July 25-26 2017
An exclusive, annual biopharma summit providing insights into the research and development of cutting edge treatments for Lung Cancer and a networking forum for precision medicine leaders in this space.
Precision: Lung Cancer will bring together scientists and business leaders from pharma, biotech and academia, using extensive networking sessions to forge meaningful collaborations.
ANTIBODY DRUG CONJUGATES
Discussions will revolve around translating the latest developments in the genomic and molecular understanding of the disease into new targeted therapies in the clinic.
Chief Medical Officer
Director, Clinical Dx Lab
Eli Lilly and Company
Wyndam Boston Beacon Hill
5 Blossom St, Boston, MA 02114, USA